Disc Medicine IRON Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Product | ||||||
| Bitopertin | $9.34M-37.2% | $14.87M+25.7% | $11.83M-50.0% | $23.69M+181% | $8.44M+14.6% | |
| DISC Three Four Zero Five | $9.19M+316% | $2.21M-81.5% | $11.91M+524% | $1.91M+14.4% | $1.67M-21.0% | |
| DISC Zero Nine Seven Four | $8.11M-14.5% | $9.48M+28.7% | $7.37M+59.7% | $4.62M-24.6% | $6.12M+45.3% | |
| Internal Research And Development | $11.31M+9.3% | $10.35M-3.3% | $10.7M+17.0% | $9.15M+35.5% | $6.75M-3.7% | |
| Other Research | $2.17M-52.6% | $4.57M+11.6% | $4.1M+32.0% | $3.1M+69.4% | $1.83M-7.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Disc Medicine break its business down?
- Disc Medicine (IRON) reports research and development expense by product across 5 parts — Bitopertin, DISC Three Four Zero Five, DISC Zero Nine Seven Four, Internal Research And Development and Other Research. Each is extracted from the segment footnotes and tracked over time.
- Where does Disc Medicine's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Disc Medicine's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.